BE Therapeutics

Q: What is BE Therapeutics's official website?

BE Therapeutics's official website is www.betherapeutics.com

Q: What is BE Therapeutics's Revenue?

BE Therapeutics's revenue is <$5 Million

Q: What is BE Therapeutics's NAICS code?

BE Therapeutics's NAICS: 54,541

Q: How many employees does BE Therapeutics have?

BE Therapeutics has 11-50 employees

Q: What industry does BE Therapeutics belong to?

BE Therapeutics is in the industry of: Business Services , Research & Development

Q: What does BE Therapeutics do?

BE Therapeutics is an early-stage biotech startup focused on engineering functional brain and spinal cord tissue to reverse damage caused by age-related conditions, stroke, trauma, and neurodegeneration. The company aims to develop replacement tissue that mimics normal developmental brain tissue, allowing for integration and recovery of lost functi... ons. Their technology is intended for pre-clinical and clinical applications, with an initial focus on replacing damaged neocortical tissue. The target clients include individuals suffering from central nervous system damage who seek innovative treatments to regain lost capabilities. Read More

Q: Is BE Therapeutics a public company?

BE Therapeutics is private company therefore does not currently have an official ticker symbol

Business Services · New York, United States · 11-50 Employees

View Company Info for Free

Overview

Headquarters

1410 Pelham Pkwy S, Bronx, New York, 104...

Website

www.betherapeutics.com

Revenue

<$5 Million

Industry

Business Services

Research & Development

ZI Rank: 1

Signal Type

Dec

Jan

Feb

Mar

Apr

May

ZI Rank

About BE Therapeutics

BE Therapeutics is an early-stage biotech startup focused on engineering functional brain and spinal cord tissue to reverse damage caused by age-related conditions, stroke, trauma, and neurodegeneration. The company aims to develop replacement tissue that mimics normal developmental brain tissue, allowing for integration and recovery of lost functions. Their technology is intended for pre-clinical and clinical applications, with an initial focus on replacing damaged neocortical tissue. The target clients include individuals suffering from central nervous system damage who seek innovative treatments to regain lost capabilities.Explore more

Is this data correct?

View contact profiles from BE Therapeutics

Popular SearchesBE TherapeuticsSIC Code 87,873NAICS Code 54,541Show more

BE Therapeutics Org Chart

Phone

Philip Ashton-Ricka...

Chief Scientific Officer

Phone

Get the full picture

Wyndham Batchelor

Lead Scientist

Phone

Scientist

Phone

Get the full picture

Is BE Therapeutics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Last 7 days

Product Launch: Get notified when BE Therapeutics launches new products

Check out if BE Therapeutics is spiking on competitors!

Check if BE Therapeutics has recently received funding, and reach out quickly before it becomes old news!

Website visits: Recent activity has been detected on your website

Funding: Get notified immidiatlly once BE Therapeutics has new funding data

Earning: See what the market has to say on BE Therapeutics recently announced quarterly report

BE Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic

Click to see if BE Therapeutics had a recent Job posting/layoffs

Congratulate Masked Content for being promoted to Masked Content at BE Therapeutics

Competitive Alert! Recent activity has been detected by your competitor Masked Content

Recommended Actions

Reach out to Masked Content who joined BE Therapeutics as Masked Content

Find 3 more new buyers

View Email Formats for BE Therapeutics

Among all Business Services companies

Low Activity

High Activity

Activity Insights

BE Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.

What does this means?

BE Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BE Therapeutics.